Lockwood G. Taylor
Lockwood G. Taylor has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Sengwee Toh
Harvard Pilgrim Health Care Institute Department of Population Medicine Boston, MA 02215
7 shared publications Susan E. Andrade
University of Massachusetts Medical School and Meyers Primary Care Institute Worcester Massachusetts USA
3 shared publicationsAndrew B. Petrone
Department of Population Medicine Harvard Medical School and Harvard Pilgrim Health Care Institute Boston Massachusetts USA
2 shared publications- David H. Smith
Kaiser Permanente Center for Health Research, Portland, Oregon
2 shared publications - Denise M. Boudreau
Kaiser Permanente Washington Health Research Institute Seattle Washington USA
2 shared publications - Gaia Pocobelli
Kaiser Permanente Washington Health Research Institute , Seattle, WA
2 shared publications
Latest Publications
- 23 August 2024
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 24 (10) , 1131-1141
Considerations for practical use of tree-based scan statistics for signal detection using electronic healthcare data: a case study with insulin glargine
Hypothesis-free signal detection (HFSD) methods such as tree-based scan statistics (TBSS) applied to longitudinal electronic healthcare data (EHD) is increasingly used in safety monitoring. However, challenges may arise in interpreting HFSD results alongside results from disproportionality analysis of spontaneous reporting. Using the anti-diabetes drug insulin glargine (Lantus®) we apply two different tree-based scan designs using TreeScan™ software on retrospective EHD and compare the results to one another as well as to results from a disproportionality analysis using SRD. The self-controlled tree temporal scan method produced the larger number of alerts relative to propensity-score matched approach; however far fewer alerts were observed when analyses were limited to EHD in inpatient/emergency room settings only. Very few reference adverse events were observed using TBSS methods on EHD relative to disproportionality methods in SRD. Differences in detected alerts between TBSS methods and between TBSS and disproportionality analysis of SRD are likely attributable to differences in data, comparator, and study design. Our results suggest that HFDS methods like TBSS applied to EHD may complement more traditional approaches such as disproportionality analysis of SRD to provide a more complete picture of product safety in the post-approval setting.
- 23 August 2024
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 24 (10) , 1131-1141
Considerations for practical use of tree-based scan statistics for signal detection using electronic healthcare data: a case study with insulin glargine
Hypothesis-free signal detection (HFSD) methods such as tree-based scan statistics (TBSS) applied to longitudinal electronic healthcare data (EHD) is increasingly used in safety monitoring. However, challenges may arise in interpreting HFSD results alongside results from disproportionality analysis of spontaneous reporting. Using the anti-diabetes drug insulin glargine (Lantus®) we apply two different tree-based scan designs using TreeScan™ software on retrospective EHD and compare the results to one another as well as to results from a disproportionality analysis using SRD. The self-controlled tree temporal scan method produced the larger number of alerts relative to propensity-score matched approach; however far fewer alerts were observed when analyses were limited to EHD in inpatient/emergency room settings only. Very few reference adverse events were observed using TBSS methods on EHD relative to disproportionality methods in SRD. Differences in detected alerts between TBSS methods and between TBSS and disproportionality analysis of SRD are likely attributable to differences in data, comparator, and study design. Our results suggest that HFDS methods like TBSS applied to EHD may complement more traditional approaches such as disproportionality analysis of SRD to provide a more complete picture of product safety in the post-approval setting.
- 5 February 2022
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 31 (5) , 534-545
Utility of fertility procedures and prenatal tests to estimate gestational age for live‐births and stillbirths in electronic health plan databases
Purpose: Current algorithms to evaluate gestational age (GA) during pregnancy rely on hospital coding at delivery and are not applicable to non‐live births. We developed an algorithm using fertility procedures and fertility tests, without relying on delivery coding, to develop a novel GA algorithm in live‐births and stillbirths.Methods: Three pregnancy cohorts were identified from 16 health‐plans in the Sentinel System: 1) hospital admissions for live‐birth, 2) hospital admissions for stillbirth, and 3) medical chart‐confirmed stillbirths. Fertility procedures and prenatal tests, recommended within specific GA windows were evaluated for inclusion in our GA algorithm. Our GA algorithm was developed against a validated delivery‐based GA algorithm in live‐births, implemented within a sample of chart‐confirmed stillbirths, and compared to national estimates of GA at stillbirth.Results: Our algorithm, including fertility procedures and 11 prenatal tests, assigned a GA at delivery to 97.9% of live‐births and 92.6% of stillbirths. For live‐births (n = 4 701 207), it estimated GA within 2 weeks of a reference delivery‐based GA algorithm in 82.5% of pregnancies, with a mean difference of 3.7 days. In chart‐confirmed stillbirths (n = 49), it estimated GA within 2 weeks of the clinically recorded GA at delivery for 80% of pregnancies, with a mean difference of 11.1 days. Implementation of the algorithm in a cohort of stillbirths (n = 40 484) had an increased percentage of deliveries after 36 weeks compared to national estimates.Conclusions: In a population of primarily commercially‐insured pregnant women, fertility procedures and prenatal tests can estimate GA with sufficient sensitivity and accuracy for utility in pregnancy studies.
- 5 February 2022
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 31 (5) , 534-545
Utility of fertility procedures and prenatal tests to estimate gestational age for live‐births and stillbirths in electronic health plan databases
Purpose: Current algorithms to evaluate gestational age (GA) during pregnancy rely on hospital coding at delivery and are not applicable to non‐live births. We developed an algorithm using fertility procedures and fertility tests, without relying on delivery coding, to develop a novel GA algorithm in live‐births and stillbirths.Methods: Three pregnancy cohorts were identified from 16 health‐plans in the Sentinel System: 1) hospital admissions for live‐birth, 2) hospital admissions for stillbirth, and 3) medical chart‐confirmed stillbirths. Fertility procedures and prenatal tests, recommended within specific GA windows were evaluated for inclusion in our GA algorithm. Our GA algorithm was developed against a validated delivery‐based GA algorithm in live‐births, implemented within a sample of chart‐confirmed stillbirths, and compared to national estimates of GA at stillbirth.Results: Our algorithm, including fertility procedures and 11 prenatal tests, assigned a GA at delivery to 97.9% of live‐births and 92.6% of stillbirths. For live‐births (n = 4 701 207), it estimated GA within 2 weeks of a reference delivery‐based GA algorithm in 82.5% of pregnancies, with a mean difference of 3.7 days. In chart‐confirmed stillbirths (n = 49), it estimated GA within 2 weeks of the clinically recorded GA at delivery for 80% of pregnancies, with a mean difference of 11.1 days. Implementation of the algorithm in a cohort of stillbirths (n = 40 484) had an increased percentage of deliveries after 36 weeks compared to national estimates.Conclusions: In a population of primarily commercially‐insured pregnant women, fertility procedures and prenatal tests can estimate GA with sufficient sensitivity and accuracy for utility in pregnancy studies.
- 24 June 2021
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 30 (11) , 1541-1550
Prevalence of prescription opioid use during pregnancy in eight US health plans during 2001–2014
Purpose: To estimate prevalence of prescription opioid use during pregnancy in eight US health plans during 2001–2014.Methods: We conducted a cohort study of singleton live birth deliveries. Maternal characteristics were ascertained from health plan and/or birth certificate data and opioids dispensed during pregnancy from health plan pharmacy records. Prevalence of prescription opioid use during pregnancy was calculated for any use, cumulative days of use, and number of dispensings.Results: We examined prevalence of prescription opioid use during pregnancy in each health plan. Tennessee Medicaid had appreciably greater prevalence of use compared to the seven other health plans. Thus, results for the two groups were reported separately. In the seven health plans (n = 587 093 deliveries), prevalence of use during pregnancy was relatively stable at 9%–11% throughout 2001–2014. In Tennessee Medicaid (n = 256 724 deliveries), prevalence increased from 29% in 2001 to a peak of 36%–37% in 2004–2010, and then declined to 28% in 2014. Use for ≥30 days during pregnancy was stable at 1% in the seven health plans and increased from 2% to 7% in Tennessee Medicaid during 2001–2014. Receipt of ≥5 opioid dispensings during pregnancy increased in the seven health plans (0.3%–0.6%) and Tennessee Medicaid (3%–5%) during 2001–2014.Conclusion: During 2001–2014, prescription opioid use during pregnancy was more common in Tennessee Medicaid (peak prevalence in late 2000s) compared to the seven health plans (relatively stable prevalence). Although a small percentage of women had opioid use during pregnancy for ≥30 days or ≥ 5 dispensings, they represent thousands of women during 2001–2014.
- 24 June 2021
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 30 (11) , 1541-1550
Prevalence of prescription opioid use during pregnancy in eight US health plans during 2001–2014
Purpose: To estimate prevalence of prescription opioid use during pregnancy in eight US health plans during 2001–2014.Methods: We conducted a cohort study of singleton live birth deliveries. Maternal characteristics were ascertained from health plan and/or birth certificate data and opioids dispensed during pregnancy from health plan pharmacy records. Prevalence of prescription opioid use during pregnancy was calculated for any use, cumulative days of use, and number of dispensings.Results: We examined prevalence of prescription opioid use during pregnancy in each health plan. Tennessee Medicaid had appreciably greater prevalence of use compared to the seven other health plans. Thus, results for the two groups were reported separately. In the seven health plans (n = 587 093 deliveries), prevalence of use during pregnancy was relatively stable at 9%–11% throughout 2001–2014. In Tennessee Medicaid (n = 256 724 deliveries), prevalence increased from 29% in 2001 to a peak of 36%–37% in 2004–2010, and then declined to 28% in 2014. Use for ≥30 days during pregnancy was stable at 1% in the seven health plans and increased from 2% to 7% in Tennessee Medicaid during 2001–2014. Receipt of ≥5 opioid dispensings during pregnancy increased in the seven health plans (0.3%–0.6%) and Tennessee Medicaid (3%–5%) during 2001–2014.Conclusion: During 2001–2014, prescription opioid use during pregnancy was more common in Tennessee Medicaid (peak prevalence in late 2000s) compared to the seven health plans (relatively stable prevalence). Although a small percentage of women had opioid use during pregnancy for ≥30 days or ≥ 5 dispensings, they represent thousands of women during 2001–2014.
- 15 September 2020
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 29 (11) , 1489-1493
Validity of diagnosis and procedure codes for identifying neural tube defects in infants
Purpose: The use of validated criteria to identify birth defects in electronic healthcare databases can avoid the cost and time‐intensive efforts required to conduct chart reviews to confirm outcomes. This study evaluated the validity of various case‐finding methodologies to identify neural tube defects (NTDs) in infants using an electronic healthcare database.Methods: This analysis used data generated from a study whose primary aim was to evaluate the association between first‐trimester maternal prescription opioid use and NTDs. The study was conducted within the Medication Exposure in Pregnancy Risk Evaluation Program. A broad approach was used to identify potential NTDs including diagnosis and procedure codes from inpatient and outpatient settings, death certificates and birth defect flags in birth certificates. Potential NTD cases were chart abstracted and confirmed by clinical experts. Positive predictive values (PPVs) and 95% confidence intervals (95% CI) are reported.Results: The cohort included 113 168 singleton live‐born infants: 55 960 infants with opioid exposure in pregnancy and 57 208 infants unexposed in pregnancy. Seventy‐three potential NTD cases were available for the validation analysis. The overall PPV was 41% using all diagnosis and procedure codes plus birth certificates. Restricting approaches to codes recorded in the infants' medical record or to birth certificate flags increased the PPVs (72% and 80%, respectively) but missed a substantial proportion of confirmed NTDs.Conclusions: Codes in electronic healthcare data did not accurately identify confirmed NTDs. These results indicate that chart review with adjudication of outcomes is important when conducting observational studies of NTDs using electronic healthcare data.
- 15 September 2020
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 29 (11) , 1489-1493
Validity of diagnosis and procedure codes for identifying neural tube defects in infants
Purpose: The use of validated criteria to identify birth defects in electronic healthcare databases can avoid the cost and time‐intensive efforts required to conduct chart reviews to confirm outcomes. This study evaluated the validity of various case‐finding methodologies to identify neural tube defects (NTDs) in infants using an electronic healthcare database.Methods: This analysis used data generated from a study whose primary aim was to evaluate the association between first‐trimester maternal prescription opioid use and NTDs. The study was conducted within the Medication Exposure in Pregnancy Risk Evaluation Program. A broad approach was used to identify potential NTDs including diagnosis and procedure codes from inpatient and outpatient settings, death certificates and birth defect flags in birth certificates. Potential NTD cases were chart abstracted and confirmed by clinical experts. Positive predictive values (PPVs) and 95% confidence intervals (95% CI) are reported.Results: The cohort included 113 168 singleton live‐born infants: 55 960 infants with opioid exposure in pregnancy and 57 208 infants unexposed in pregnancy. Seventy‐three potential NTD cases were available for the validation analysis. The overall PPV was 41% using all diagnosis and procedure codes plus birth certificates. Restricting approaches to codes recorded in the infants' medical record or to birth certificate flags increased the PPVs (72% and 80%, respectively) but missed a substantial proportion of confirmed NTDs.Conclusions: Codes in electronic healthcare data did not accurately identify confirmed NTDs. These results indicate that chart review with adjudication of outcomes is important when conducting observational studies of NTDs using electronic healthcare data.
- 4 June 2019
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 80 (4)
Antipsychotic Use and Stroke
From The Journal of Clinical Psychiatry: Research on antipsychotics and stoke risk has focused on elderly demented patients, who have higher stroke risk than younger patients. This study compared stroke risk between typical and atypical antipsychotics in non-demented, non-elderly individuals.
- 4 June 2019
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 80 (4)
Antipsychotic Use and Stroke
From The Journal of Clinical Psychiatry: Research on antipsychotics and stoke risk has focused on elderly demented patients, who have higher stroke risk than younger patients. This study compared stroke risk between typical and atypical antipsychotics in non-demented, non-elderly individuals.
- 13 November 2018
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 27 (12) , 1416-1421
Overall and cause‐specific mortality in the Sentinel system: A power analysis
Purpose: Mortality data within the Sentinel Death Tables remain generally uncharacterized. Assessment of mortality data within Sentinel will help inform its utility for medical product safety studies.Methods: To determine if Sentinel contains sufficient all‐cause and cause‐specific mortality events to power postmarketing safety studies.We calculated crude rates of all‐cause mortality and suicide and proportional mortality from suicide from 2004 to 2012 in seven Sentinel data partners. Results were stratified by data partner, sex, age group, and calendar year and compared with national estimates from Centers for Disease Control and Prevention Wide‐ranging ONline Data for Epidemiologic Research. We performed sample size estimations for all‐cause mortality and 10 leading causes of death.Results: We observed 479 694 deaths, including 5811 suicides, during 68 million person‐years of follow‐up. Pooled mean death and suicide rates in the data partners were 710 and 8.6 per 100 000 person‐years, respectively (vs 810 and 11.8 nationally). The mean proportional mortality from suicide among the data partners was 1.2%, compared with 1.5% nationally. National trends of decreasing overall mortality and increasing proportional mortality for suicide were reflected within Sentinel. We estimated that detecting hazard ratios of 1.25 and 3 would require 16 442 and 460 exposed patients, respectively, for overall mortality, and 1.3 million and 37 411, respectively, for suicide.Conclusions: This was the first study to investigate mortality data in the Sentinel death tables. We found that all‐cause mortality appeared well powered for use as a safety outcome and cause‐specific mortality outcomes may be adequately powered in certain circumstances. Further investigation into the quality of the Sentinel death data is needed.
- 13 November 2018
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 27 (12) , 1416-1421
Overall and cause‐specific mortality in the Sentinel system: A power analysis
Purpose: Mortality data within the Sentinel Death Tables remain generally uncharacterized. Assessment of mortality data within Sentinel will help inform its utility for medical product safety studies.Methods: To determine if Sentinel contains sufficient all‐cause and cause‐specific mortality events to power postmarketing safety studies.We calculated crude rates of all‐cause mortality and suicide and proportional mortality from suicide from 2004 to 2012 in seven Sentinel data partners. Results were stratified by data partner, sex, age group, and calendar year and compared with national estimates from Centers for Disease Control and Prevention Wide‐ranging ONline Data for Epidemiologic Research. We performed sample size estimations for all‐cause mortality and 10 leading causes of death.Results: We observed 479 694 deaths, including 5811 suicides, during 68 million person‐years of follow‐up. Pooled mean death and suicide rates in the data partners were 710 and 8.6 per 100 000 person‐years, respectively (vs 810 and 11.8 nationally). The mean proportional mortality from suicide among the data partners was 1.2%, compared with 1.5% nationally. National trends of decreasing overall mortality and increasing proportional mortality for suicide were reflected within Sentinel. We estimated that detecting hazard ratios of 1.25 and 3 would require 16 442 and 460 exposed patients, respectively, for overall mortality, and 1.3 million and 37 411, respectively, for suicide.Conclusions: This was the first study to investigate mortality data in the Sentinel death tables. We found that all‐cause mortality appeared well powered for use as a safety outcome and cause‐specific mortality outcomes may be adequately powered in certain circumstances. Further investigation into the quality of the Sentinel death data is needed.
- 8 March 2018
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 27 (6) , 604-611
Utilization of drugs with pregnancy exposure registries during pregnancy
Purpose: To describe the utilization of drugs with pregnancy exposure registries by trimester during pregnancy, in comparison with matched nonpregnant episodes and a pre‐pregnancy period.Methods: We identified live‐born deliveries from women aged 10 to 54 years and matched the pregnancies 1:1 with nonpregnant episodes from a comparator cohort not delivering live‐born infants, using data from 2001 to 2013 in the Sentinel Distributed Database. We evaluated the utilization of 34 drugs with pregnancy exposure registries, comparing utilization during pregnancy to the matched nonpregnant episodes, and to the 90 days before pregnancy.Results: We identified 1 895 597 pregnancies ending in live births in 1 598 697 women and 1 895 597 matched nonpregnant episodes in 1 582 581 women. We observed a lower prevalence of use for most drugs during pregnancy compared with the matched nonpregnant episodes, and the 90‐day pre‐pregnancy period. The median (interquartile range) prevalence ratio of use, at any time during pregnancy, for all products was 0.2 (0.1‐0.3) comparing pregnant to nonpregnant episodes. Overall, there was a decrease in drug utilization by trimester; from 2.6% in the 90 days preceding pregnancy to 2.1% in the first trimester, 1.1% in the second trimester, and 0.9% in the third trimester.Conclusions: Among drugs with pregnancy exposure registries, use was less during pregnancy compared with before pregnancy and to the matched nonpregnant episodes. The lower utilization during pregnancy suggests that women may be avoiding these drugs to minimize potentially harmful exposure during pregnancy. This lower utilization may increase the challenges of further studying the safety of these drugs using pregnancy exposure registries.
- 8 March 2018
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 27 (6) , 604-611
Utilization of drugs with pregnancy exposure registries during pregnancy
Purpose: To describe the utilization of drugs with pregnancy exposure registries by trimester during pregnancy, in comparison with matched nonpregnant episodes and a pre‐pregnancy period.Methods: We identified live‐born deliveries from women aged 10 to 54 years and matched the pregnancies 1:1 with nonpregnant episodes from a comparator cohort not delivering live‐born infants, using data from 2001 to 2013 in the Sentinel Distributed Database. We evaluated the utilization of 34 drugs with pregnancy exposure registries, comparing utilization during pregnancy to the matched nonpregnant episodes, and to the 90 days before pregnancy.Results: We identified 1 895 597 pregnancies ending in live births in 1 598 697 women and 1 895 597 matched nonpregnant episodes in 1 582 581 women. We observed a lower prevalence of use for most drugs during pregnancy compared with the matched nonpregnant episodes, and the 90‐day pre‐pregnancy period. The median (interquartile range) prevalence ratio of use, at any time during pregnancy, for all products was 0.2 (0.1‐0.3) comparing pregnant to nonpregnant episodes. Overall, there was a decrease in drug utilization by trimester; from 2.6% in the 90 days preceding pregnancy to 2.1% in the first trimester, 1.1% in the second trimester, and 0.9% in the third trimester.Conclusions: Among drugs with pregnancy exposure registries, use was less during pregnancy compared with before pregnancy and to the matched nonpregnant episodes. The lower utilization during pregnancy suggests that women may be avoiding these drugs to minimize potentially harmful exposure during pregnancy. This lower utilization may increase the challenges of further studying the safety of these drugs using pregnancy exposure registries.
- Open Access
- 21 February 2017
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 26 (5) , 592-596
Antiemetic use among pregnant women in the United States: the escalating use of ondansetron
Purpose: To examine ondansetron use in pregnancy in the context of other antiemetic use among a large insured United States population of women delivering live births.Methods: We assessed ondansetron and other antiemetic use among pregnant women delivering live births between 2001 and 2015 in 15 data partners contributing data to the Mini‐Sentinel Distributed Database. We identified live birth pregnancies using a validated algorithm, and all forms of ondansetron and other available antiemetics were identified using National Drug Codes or procedure codes. We assessed the prevalence of antiemetic use by trimester, calendar year, and formulation.Results: In over 2.3 million pregnancies, the prevalence of ondansetron, promethazine, metoclopramide, or doxylamine/pyridoxine use anytime in pregnancy was 15.2, 10.3, 4.0, and 0.4%, respectively. Ondansetron use increased from <1% of pregnancies in 2001 to 22.2% in 2014, with much of the increase attributable to oral ondansetron beginning in 2006. Promethazine and metoclopramide use increased modestly between 2001 (13.8%, 3.2%) and 2006 (16.0%, 6.0%) but decreased annually through 2014 (8.0%, 3.2%). Doxylamine/pyridoxine, approved for management of nausea and vomiting in pregnancy in 2013, was used in 1.8% of pregnancies in 2014. For all antiemetics, use was highest in the first trimester.Conclusions: We observed a marked increase in ondansetron use by study year, prescribed to nearly one‐quarter of insured pregnant women in 2014, occurring in conjunction with decreased use of promethazine and metoclopramide. Given the widespread use of ondansetron in pregnancy, data establishing product efficacy and methodologically rigorous evaluation of post‐marketing safety are needed. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
- 21 February 2017
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 26 (5) , 592-596
Open AccessAntiemetic use among pregnant women in the United States: the escalating use of ondansetron
Purpose: To examine ondansetron use in pregnancy in the context of other antiemetic use among a large insured United States population of women delivering live births.Methods: We assessed ondansetron and other antiemetic use among pregnant women delivering live births between 2001 and 2015 in 15 data partners contributing data to the Mini‐Sentinel Distributed Database. We identified live birth pregnancies using a validated algorithm, and all forms of ondansetron and other available antiemetics were identified using National Drug Codes or procedure codes. We assessed the prevalence of antiemetic use by trimester, calendar year, and formulation.Results: In over 2.3 million pregnancies, the prevalence of ondansetron, promethazine, metoclopramide, or doxylamine/pyridoxine use anytime in pregnancy was 15.2, 10.3, 4.0, and 0.4%, respectively. Ondansetron use increased from <1% of pregnancies in 2001 to 22.2% in 2014, with much of the increase attributable to oral ondansetron beginning in 2006. Promethazine and metoclopramide use increased modestly between 2001 (13.8%, 3.2%) and 2006 (16.0%, 6.0%) but decreased annually through 2014 (8.0%, 3.2%). Doxylamine/pyridoxine, approved for management of nausea and vomiting in pregnancy in 2013, was used in 1.8% of pregnancies in 2014. For all antiemetics, use was highest in the first trimester.Conclusions: We observed a marked increase in ondansetron use by study year, prescribed to nearly one‐quarter of insured pregnant women in 2014, occurring in conjunction with decreased use of promethazine and metoclopramide. Given the widespread use of ondansetron in pregnancy, data establishing product efficacy and methodologically rigorous evaluation of post‐marketing safety are needed. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
- 31 March 2015
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 24 (5) , 510-517
Development of a mother-child database for drug exposure and adverse event detection in the Military Health System
Purpose The aim of this study was to develop a mother-child linked database consisting of all eligible active duty military personnel, retirees, and their dependents in order to conduct medication-related analyses to improve the safety and quality of care in the Military Health System (MHS). Methods Eligible women of reproductive age with at least one pregnancy-related encounter between January 2005 and December 2013 receiving care in the MHS were included in the study population. Building on previously published algorithms, we used pregnancy-related diagnostic and procedure codes, parameterized temporal constraints, and data elements unique to the MHS to identify pregnancies ending in live births, stillbirth, spontaneous abortion, or ectopic pregnancy. Pregnancies ending in live births were matched to presumptive offspring using birth dates and family-based sponsorship identification. Antidepressant and antiepileptic use during pregnancy was evaluated using electronic pharmacy data. Results Algorithms identified 755,232 women who experienced 1,099,648 complete pregnancies with both pregnancy care encounter and pregnancy outcome. Of the 924,320 live birth pregnancies, 827,753 (90.0%) were matched to offspring. Algorithms also identified 5,663 stillbirths, 11,358 ectopic pregnancies, and 169,665 spontaneous abortions. Among the matched singleton live birth pregnancies, 7.1% of mothers were dispensed an antidepressant at any point during pregnancy, usually a selective serotonin reuptake inhibitor, (75.3%), whereas 1.3% of mothers were dispensed an antiepileptic drug. Copyright © 2015 John Wiley & Sons, Ltd.
- 31 March 2015
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 24 (5) , 510-517
Development of a mother-child database for drug exposure and adverse event detection in the Military Health System
Purpose The aim of this study was to develop a mother-child linked database consisting of all eligible active duty military personnel, retirees, and their dependents in order to conduct medication-related analyses to improve the safety and quality of care in the Military Health System (MHS). Methods Eligible women of reproductive age with at least one pregnancy-related encounter between January 2005 and December 2013 receiving care in the MHS were included in the study population. Building on previously published algorithms, we used pregnancy-related diagnostic and procedure codes, parameterized temporal constraints, and data elements unique to the MHS to identify pregnancies ending in live births, stillbirth, spontaneous abortion, or ectopic pregnancy. Pregnancies ending in live births were matched to presumptive offspring using birth dates and family-based sponsorship identification. Antidepressant and antiepileptic use during pregnancy was evaluated using electronic pharmacy data. Results Algorithms identified 755,232 women who experienced 1,099,648 complete pregnancies with both pregnancy care encounter and pregnancy outcome. Of the 924,320 live birth pregnancies, 827,753 (90.0%) were matched to offspring. Algorithms also identified 5,663 stillbirths, 11,358 ectopic pregnancies, and 169,665 spontaneous abortions. Among the matched singleton live birth pregnancies, 7.1% of mothers were dispensed an antidepressant at any point during pregnancy, usually a selective serotonin reuptake inhibitor, (75.3%), whereas 1.3% of mothers were dispensed an antiepileptic drug. Copyright © 2015 John Wiley & Sons, Ltd.